Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cel-Sci Corporation Common Stock
(NY:
CVM
)
5.150
+0.160 (+3.21%)
Official Closing Price
Updated: 8:00 PM EST, Jan 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cel-Sci Corporation Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
June 18, 2024
From
CEL-SCI Corporation
Via
Business Wire
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
June 06, 2024
From
CEL-SCI Corporation
Via
Business Wire
CVM Stock Earnings: CEL-SCI Reported Results for Q2 2024
↗
May 16, 2024
CEL-SCI just reported results for the second quarter of 2024.
Via
InvestorPlace
Why CEL-SCI Corporation (CVM) Shares Are Diving
↗
February 09, 2024
CEL-SCI Corporation shares are trading lower by 13.9% Friday morning. The company priced an offering of 3.875 million shares.
Via
Benzinga
CVM Stock Earnings: CEL-SCI Reported Results for Q4 2023
↗
December 27, 2023
CEL-SCI just reported results for the fourth quarter of 2023.
Via
InvestorPlace
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
May 16, 2024
From
CEL-SCI Corporation
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
May 09, 2024
Via
Benzinga
Why CEL-SCI (CVM) Shares Are Trading Higher
↗
May 08, 2024
CEL-SCI shares are trading higher by 18.6% during Wednesday's session. The company received positive feedback from the FDA regarding their cancer immunotherapy.
Via
Benzinga
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
May 08, 2024
From
CEL-SCI Corporation
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
May 08, 2024
Via
Benzinga
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
April 23, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
March 19, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Issues Letter to Shareholders
March 06, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
February 15, 2024
From
CEL-SCI Corporation
Via
Business Wire
InvestorNewsBreaks – CEL-SCI Corporation (NYSE American: CVM) Closes on $7.75M Public Offering
February 14, 2024
Via
Investor Brand Network
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
February 13, 2024
From
CEL-SCI Corporation
Via
Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
↗
February 09, 2024
Via
Benzinga
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
February 09, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
February 06, 2024
From
CEL-SCI Corporation
Via
Business Wire
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
January 31, 2024
From
CEL-SCI Corporation
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
December 28, 2023
Via
Benzinga
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
December 22, 2023
From
CEL-SCI Corporation
Via
Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
↗
December 04, 2023
Via
Benzinga
Why Is Cancer Focused CEL-SCI Stock Trading Higher Today?
↗
December 04, 2023
CEL-SCI Corporation (AMEX: CVM) announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine (Leukocyte Interleukin, Injection) to be evaluated as the...
Via
Benzinga
Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
December 04, 2023
Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of registered follow-on offering of 10 million units at a purchase price of $1.20...
Via
Benzinga
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
December 04, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
November 20, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
November 16, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Issues Letter to Shareholders
October 30, 2023
From
CEL-SCI Corporation
Via
Business Wire
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments
October 24, 2023
EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END
Via
FinancialNewsMedia
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
